Ozempic in Queens, NYthe straight answer, from a physician
Ozempic® is FDA-approved for type 2 diabetes — not for weight loss. Wegovy® is the same molecule approved for weight management. What Dr. Keisha Bryant, MD prescribes is physician-managed semaglutide: the same active ingredient, from a licensed U.S. pharmacy, with a board-certified MD adjusting your dose every month.
- Blood-sugar control in adults with type 2 diabetes
- Lowering cardiovascular risk in adults with type 2 diabetes and known heart disease
- Since January 2025, slowing kidney decline in adults with type 2 diabetes and chronic kidney disease
- Not FDA-approved as a weight-loss medication — that indication belongs to Wegovy
Physician-prescribed semaglutide — the same active ingredient as Ozempic and Wegovy — dispensed by a licensed U.S. pharmacy and supervised monthly by Dr. Bryant.
Why searching “Ozempic near me” gets confusing
Ozempic became a household word for weight loss, but that is not what it is licensed for. The FDA approved it to improve blood sugar in adults with type 2 diabetes, later to reduce the risk of serious cardiovascular events in adults who have both type 2 diabetes and established heart disease, and in January 2025 to slow kidney decline in adults with type 2 diabetes and chronic kidney disease. Every one of those indications begins with diabetes. Weight loss was something clinicians and patients observed along the way, not the indication on the label.
So the manufacturer studied the same molecule at a higher dose specifically for weight, and that product is Wegovy. Same active ingredient — semaglutide. Different name, different dosing schedule, different approved use. If you searched for Ozempic because you want to lose weight, the medication you were actually looking for is the semaglutide behind both names.
That is what this practice prescribes: physician-prescribed semaglutide, the same active ingredient as the FDA-approved brands, dispensed by a licensed U.S. pharmacy and supervised by a board-certified MD. No pretending, no drop-shipped pen from a website that disappears when you have a question at week three.
Ozempic vs Wegovysame molecule, different job
| Ozempic® | Wegovy® | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved for | Type 2 diabetes; cardiovascular risk reduction in type 2 diabetes with heart disease; kidney-disease progression in type 2 diabetes with CKD | Chronic weight management; cardiovascular risk reduction in adults with overweight or obesity and heart disease |
| Typical maintenance dose | Lower | Higher |
| Manufacturer | Novo Nordisk | Novo Nordisk |
Want the longer version? Read Ozempic vs Wegovy: two brands, one molecule on the blog.
What you actually getfor $180 a month
One transparent price with the medication and the physician both included. The oversight is the point — a GLP-1 without dose management is just an expensive pen.
- Physician-prescribed semaglutide — same active ingredient as Ozempic and Wegovy, from a licensed U.S. pharmacy
- Monthly visit with Dr. Bryant — in the St Albans office or by video
- Slow dose titration over 4–8 weeks, which is what keeps nausea manageable
- Lab monitoring when medically needed
- Nutrition and lifestyle plan built around how you actually eat
- Unlimited messaging between visits for side-effect questions
Prefer the stronger dual-action option? Tirzepatide is $190/month. Dr. Bryant recommends a starting point at your consult.
What the evidence shows
In the STEP clinical-trial program, participants taking semaglutide lost an average of roughly 10–15% of body weight over 68 weeks, alongside diet and activity changes. Those are trial averages and not a guarantee — individual results vary. What changes the odds is the part people skip: starting low, titrating slowly, and having someone review your progress every single month.
Typical eligibility
Generally a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. BMI is a screening tool, not a diagnosis — final eligibility is Dr. Bryant’s call after she reviews your full history. Not sure where you land? Use the GLP-1 eligibility guide.
Talk to us first if…
- · You are pregnant, breastfeeding, or planning a pregnancy
- · You have a personal or family history of medullary thyroid cancer or MEN2
- · You have a history of pancreatitis
- · You take other medications that may interact
None of these are automatic disqualifiers. They are reasons to have a careful conversation with a physician before anything is prescribed — which is exactly what the free consult is for.
Getting semaglutide in Queens without the runaround
Southeast Queens has plenty of people on GLP-1 medication and very few places to be actually seen about it. The telehealth apps mail a pen and hand you a chatbot. The big hospital systems put a three-month wait between you and an endocrinologist. Neither is much help at week three when the nausea hits and you are wondering whether to hold the dose.
Dr. Bryant Medical Practice and MedSpa is at 205-15 Hollis Avenue, St Albans, NY 11412 — a short drive from Hollis, Jamaica, Cambria Heights, Springfield Gardens, Queens Village, Laurelton and Rosedale. Dr. Keisha Bryant is board-certified in internal medicine, and she is the one managing your dose — not a rotating panel of names you never meet.
If the monthly visit is easier from your kitchen table, take it by virtual video visit instead. Either way, start with a free 15-minute consult and an honest answer about whether this is right for you.
Keep reading
Full clinical breakdown, what's included, and pricing.
Line-by-line cost comparison against retail and online sellers.
The weight-management approval, and the heart-risk indication.
Two brands, one molecule — the differences that matter.
Common questions
References & sources
- U.S. Food and Drug Administration — Ozempic (semaglutide) approval record, Drugs@FDA
- U.S. Food and Drug Administration — First treatment approved to reduce cardiovascular risk in adults with obesity or overweight (Wegovy, March 2024)
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine
- National Institute of Diabetes and Digestive and Kidney Diseases — Prescription medications to treat overweight and obesity
Get a straight answer about GLP-1 medication.
Book a free 15-minute consult with Dr. Keisha Bryant, MD in St Albans. She reviews your history, explains what's realistic, and tells you honestly if semaglutide isn't the right fit.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Dr. Bryant Medical Practice and MedSpa is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names are used here only to identify the medications patients ask about. This page is general health information, not medical advice, and does not replace a consultation with a licensed physician.